CLOSEOUT LETTER
NEwhere Inc. d/b/a Mad Hatter Juice MARCS-CMS 548076 —
- Recipient:
- NEwhere Inc. d/b/a Mad Hatter Juice
United States
- Issuing Office:
United States
|
|
|
|
U.S. Food & Drug Administration
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring, MD 20993
|
VIA UPS and Electronic Mail
Ali Esmaili
NEwhere Inc. d/b/a Mad Hatter Juice
19801 Nordhoff Pl #107
Chatsworth, CA 91311
info@MadHatterJuice.com
ali@newhere.com
RE: Warning Letter issued to NEwhere Inc. d/b/a Mad Hatter Juice (RW 1800836)
Dear Ali Esmaili:
On May 1, 2018, the United States Food and Drug Administration’s (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your One Mad Hit Juice Box e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your One Mad Hit Juice Box e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children.
On May 10, 2018, you sent FDA a response to the Warning Letter. In response to the Warning Letter, you stated that you implemented corrective actions to address the violation identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violation identified in the Warning Letter. We note that you may have other tobacco products with labeling and/or advertising that causes the product to be misbranded for similar reasons to those discussed above. You are responsible for taking any necessary actions to bring your tobacco products into compliance with the requirements of the law.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.
Should you have any questions or concerns, please contact me at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov.
Sincerely,
/s/
Ele Ibarra-Pratt
/s/
Ele Ibarra-Pratt
Division Director
Office of Compliance and Enforcement
Center for Tobacco Products
VIA UPS and Electronic Mail
cc:
VapeCo Distribution LLC
Attn: Jameson Rodgers
9301 Oakdale Ave Suite #104
Chatsworth, CA 91311
One Hit Wonder Holdings, LLC
Attn: Andrew Gale
1820 W. Orangewood Ave, Ste 104B
Orange, CA 92868
GoDaddy.com, LLC
abuse@godaddy.com
Shopify Inc.
abuse@shopify.com